Curis Inc.
| NASDAQ: CRIS | Healthcare / Biotechnology / USA |
| 12.35 | +0.3800 | +3.17% | Vol 105.76K | 1Y Perf 1 450.12% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 11.51 | ASK | 12.41 | ||
| Open | 12.09 | Previous Close | 11.97 | ||
| Pre-Market | - | After-Market | 12.18 | ||
| - - | -0.17 -1.38% |
| Target Price | 6.00 | Analyst Rating | Strong Buy 1.50 | |
| Potential % | -51.42 | Finscreener Ranking | ★★★ 49.48 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★+ 53.27 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★+ 40.61 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 52.78 | Earnings Rating | Sell | |
| Market Cap | 72.66M | Earnings Date | 2nd Nov 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.66 | |
| Beta | 3.14 |
Today's Price Range 12.0612.99 | 52W Range 3.8020.00 | 5 Year PE Ratio Range -6.60-2.90 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 47.37% | ||
| 1 Month | 194.75% | ||
| 3 Months | 2 045.21% | ||
| 6 Months | 1 440.67% | ||
| 1 Year | 1 450.12% | ||
| 3 Years | 751.72% | ||
| 5 Years | 1 336.05% | ||
| 10 Years | -22.81% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -63.49 | |||
ROE last 12 Months | -82.51 | |||
ROA (5Y Avg) | -12.86 | |||
ROA last 12 Months | -43.90 | |||
ROC (5Y Avg) | -73.79 | |||
ROC last 12 Months | -65.89 | |||
Return on invested Capital Q | -19.94 | |||
Return on invested Capital Y | -12.33 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.00 | ||||
| 1.13 | ||||
| 8.48 | ||||
| 36.40 | ||||
| -1.50 | ||||
| -0.55 | ||||
| 1.35 | ||||
| 0.58 | ||||
| -31 366 400.00 | ||||
| Forward PE | -1.62 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.40 | ||||
| 7.70 | ||||
| 0.05 | ||||
| 0.08 | ||||
| -13.00 | ||||
| Leverage Ratio | 2.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 96.70 | ||||
| -525.80 | ||||
| -524.10 | ||||
| -376.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.28M | ||||
| 0.08 | ||||
| 2.88 | ||||
| 4.09 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -2.32 | -2.13 | 8.19 |
| Q02 2023 | -2.40 | -2.40 | 0.00 |
| Q01 2023 | -2.20 | -2.40 | -9.09 |
| Q04 2022 | -2.80 | -2.40 | 14.29 |
| Q03 2022 | -3.40 | -2.80 | 17.65 |
| Q02 2022 | -3.40 | -3.40 | 0.00 |
| Q01 2022 | -0.17 | -0.18 | -5.88 |
| Q04 2021 | -0.13 | -0.15 | -15.38 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -2.03 | 11.74 | Positive |
| 12/2023 FY | -9.09 | 1.94 | Positive |
| 3/2024 QR | -2.09 | 5.00 | Positive |
| 12/2024 FY | -5.20 | 38.10 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -2.32 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 105.76K |
| Shares Outstanding | 5.88K |
| Shares Float | 5.18M |
| Trades Count | 1.23K |
| Dollar Volume | 1.32M |
| Avg. Volume | 158.11K |
| Avg. Weekly Volume | 140.12K |
| Avg. Monthly Volume | 162.54K |
| Avg. Quarterly Volume | 171.66K |
Curis Inc. (NASDAQ: CRIS) stock closed at 12.35 per share at the end of the most recent trading day (a 3.17% change compared to the prior day closing price) with a volume of 105.76K shares and market capitalization of 72.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 28 people. Curis Inc. CEO is James E. Dentzer.
The one-year performance of Curis Inc. stock is 1450.12%, while year-to-date (YTD) performance is 2145.45%. CRIS stock has a five-year performance of 1336.05%. Its 52-week range is between 3.8 and 20, which gives CRIS stock a 52-week price range ratio of 52.78%
Curis Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 8.48, a price to cashflow ratio of 36.40, a PEG ratio of -, a ROA of -43.90%, a ROC of -65.89% and a ROE of -82.51%. The company’s profit margin is -%, its EBITDA margin is -524.10%, and its revenue ttm is $7.28 Million , which makes it $0.08 revenue per share.
Of the last four earnings reports from Curis Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-2.32 for the next earnings report. Curis Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Curis Inc. is Strong Buy (1.5), with a target price of $6, which is -51.42% compared to the current price. The earnings rating for Curis Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Curis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Curis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.60, ATR14 : 1.19, CCI20 : 193.10, Chaikin Money Flow : -0.13, MACD : 1.59, Money Flow Index : 82.01, ROC : 92.75, RSI : 87.41, STOCH (14,3) : 92.35, STOCH RSI : 1.00, UO : 50.31, Williams %R : -7.65), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Curis Inc. in the last 12-months were:
Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
CEO: James E. Dentzer
Telephone: +1 617 503-6500
Address: 4 Maguire Road, Lexington 02421, MA, US
Number of employees: 28
TipRanks News for CRIS
Fri, 29 Sep 2023 15:36 GMT Buy Rating for Curis (CRIS) Amidst Reverse Stock Split and Revised Launch Estimates for Key Product, Emavusertib
- TipRanks. All rights reserved.Fri, 07 Jul 2023 10:15 GMT Curis (CRIS) Receives a Buy from H.C. Wainwright
- TipRanks. All rights reserved.
